Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 4.7% – Time to Sell?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price fell 4.7% during trading on Thursday . The stock traded as low as $11.65 and last traded at $11.65. 788 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 13,410 shares. The stock had previously closed at $12.22.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

The company has a 50 day simple moving average of $11.47 and a two-hundred day simple moving average of $10.99. The company has a market cap of $3.87 billion and a PE ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.